In this article, we’ll look at the Wall Street ratings, recommendations, and target prices for Baxter International (BAX) over the next 12 months. On October 13, 2017, in a Reuters survey comprising 17 brokerages, six (~35.3%) analysts rated Baxter International as a “buy.”
Ten (~58.8%) analysts gave the company a “hold” rating. Only one analyst provided a “sell” recommendation on BAX stock.
According to the analysts’ recommendations, Baxter International’s consensus 12-month target price is $67.20 per share. This compares to BAX stock’s closing price of $62.50 on October 12, 2017. The return potential of investment in Baxter International stock over the next 12 months is 7.5%.
Target prices and revised recommendations
According to the latest recommendations, analysts provided the lowest 12-month target price of $33.00 to BAX stock, implying a maximum downside risk of around -47.2%. However, the highest target price on the stock is $71.00, which represents a maximum 12-month return potential of 13.6%.
On October 3, 2017, Royal Bank of Canada reiterated its “hold” rating on BAX stock. The company has a target price of $60.00 on the stock.
Citigroup initiated coverage on Baxter International on August 17, 2017. It has a “neutral” rating on BAX stock with a target price of $63.00 per share.
On October 13, 2017, peers Becton, Dickinson and Co. (BDX), ResMed (RMD), and Thermo Fisher Scientific (TMO) had average broker target prices of $207.88, $69.16, and $209.54, respectively. These targets imply one-year return potential figures of 4.6%, -10.9%, and 8.4%, respectively.
Investors seeking diversified exposure on Baxter International can check out the iShares Edge MSCI Min Vol USA ETF (USMV). BAX makes up ~0.66% of IWD’s total holdings.